Literature DB >> 26716808

Synchronous Onset of Cytomegalovirus Colitis and Ulcerative Colitis in an Immunocompetent Patient: A Case Report.

S Yangzhen1, K Liu2, T Xu1, Y Yang1, Y Zhang3.   

Abstract

Cytomegalovirus (CMV) infection has been associated with ulcerative colitis (UC). The prevalence of CMV infection in UC patients ranges from 10% to 16%. It is particularly high in the patients with steroidrefractory UC and those treated with immunosuppressants. However, synchronous onset of CMV colitis and UC in an immunocompetent patient is rare. It was originally described in 1990 and since then sixteen cases have been reported, as far as we are aware. Here, we present a case of CMV colitis and UC synchronously developing in an elderly immunocompetent woman. She was diagnosed through tissue immunohistochemistry and successfully treated with intravenous ganciclovir. This case demonstrates that in patients with severe active UC, even with new onset of the disease, CMV infection needs to be ruled out before initiating an aggressive immunosuppressive therapy.

Entities:  

Keywords:  Cytomegalovirus infection; immunocompetent; ulcerative colitis

Year:  2015        PMID: 26716808     DOI: 10.7727/wimj.2015.307

Source DB:  PubMed          Journal:  West Indian Med J        ISSN: 0043-3144            Impact factor:   0.171


  3 in total

1.  Cytomegalovirus enterocolitis with subsequent diagnosis of coexisting new-onset inflammatory bowel disease: Two case reports and review of the literature.

Authors:  Panupong Luangsirithanya; Sukrit Treewaree; Ananya Pongpaibul; Nonthalee Pausawasdi; Julajak Limsrivilai
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

2.  CMV Colitis in Immunocompetent Patients: 2 Cases of a Diagnostic Challenge.

Authors:  Maria Paparoupa; Viola Schmidt; Helgard Weckauf; Huy Ho; Frank Schuppert
Journal:  Case Rep Gastrointest Med       Date:  2016-04-12

3.  Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug.

Authors:  Fidencio Davalos; Benjamin Chaucer; Wahib Zafar; Shamim Salman; Jay Nfonoyim
Journal:  Transl Oncol       Date:  2016-06       Impact factor: 4.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.